Solid Biosciences reports positive interim SGT-003 data; microdystrophin expression 60% at Day 90, 91% at Day 360

Solid Biosciences Inc.

40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.
Day 90 biopsy (n=20): mean microdystrophin expression 60% (western blot), 63% positive fibers; 60% beta-sarcoglycan restoration.
Day 360 biopsy (n=3): microdystrophin expression 91% (western blot), 69% positive fibers; 69% beta-sarcoglycan restoration.
Biomarker improvements: CK -38%, ALT -43%, AST -30%, LDH -46%, eMHC -44% at Day 90.
FDA aligned on Phase 3 design; screening underway; first participant dosing expected Q1 2026; accelerated approval discussions planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.